KAI-407
KAI-407 is an orally active inhibitor of Plasmodium PI4K kinase, which can broadly inhibit multiple stages of the parasite lifecycle. KAI-407 exhibits EC50s of for the blood stage of malignant Plasmodium of 81 nM; for the liver schizonts of P. yoelii of 88 nM; and IC50s for the liver schizonts and dormant bodies of P. cynomolgi of 0.64 μM and 0.69 μM respectively. KAI-407 can prevent Plasmodium berghei infection 100%. KAI-407 can be used for the study of vivax malaria.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 1513879-18-9
- Formel: C22H14F3N5O
- Molecular Weight:421.37
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle Parasite Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Chemical Information
-
CAS. Nr. 1513879-18-9
-
Molecular Weight 421.37
-
Formel C22H14F3N5O
-
SMILES
O=C(C1=CN2C(C=N1)=NC=C2C3=CC=C(C(F)(F)F)C=C3)N(C4=CC=C(C#N)C=C4)C
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Zou B, et al. Lead optimization of imidazopyrazines: a new class of antimalarial with activity on Plasmodium liver stages. ACS Med Chem Lett. 2014 Jul 6;5(8):947-50. [Content Brief]
[2]. Zeeman AM, et al. KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro. Antimicrob Agents Chemother. 2014;58(3):1586-95. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)